<DOC>
	<DOC>NCT01497561</DOC>
	<brief_summary>This trial is conducted in Europe. The aim of this trial is to investigate the pharmacodynamics and pharmacokinetics of single doses of insulin detemir and insulin NPH in subjects with type 2 diabetes.</brief_summary>
	<brief_title>Pharmacodynamics and Pharmacokinetics of Insulin Detemir in Subjects With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Isophane insulin, beef</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Detemir</mesh_term>
	<mesh_term>Isophane Insulin, Human</mesh_term>
	<mesh_term>Insulin, Isophane</mesh_term>
	<criteria>Type 2 diabetes Subjects treated with insulin for minimum 3 months Duration of diabetes for at least 12 months Body Mass Index (BMI) below 30 kg/m^2 HbA1c maximum 10% based on analysis from central laboratory Current treatment with insulin above 1.2 U/kg/day Current treatment with insulin glargine Current treatment with drugs known to interfere with glucose metabolism Current treatment with oral antidiabetic drugs</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>